BACKGROUND: There is a paucity of published data regarding the quality of care of inflammatory bowel disease (IBD) in Canada. Clinical quality indicators are quantitative end points used to guide, monitor and improve the quality of patient care. In Canada, where universal health care can vary significantly among provinces, quality indicators can be used to identify potential gaps in the delivery of IBD care and standardize the approach to interprovincial management. METHODS: The Emerging Practice in IBD Collaborative (EPIC) group generated a shortlist of IBD quality indicators based on a comprehensive literature review. An iterative voting process was used to select quality indicators to take forward. In a face-to-face meeting with the EPIC group, available evidence to support each quality indicator was presented by the EPIC member aligned to it, followed by group discussion to agree on the wording of the statements. The selected quality indicators were then ratified in a final vote by all EPIC members. RESULTS: Eleven quality indicators for the management of IBD within the single-payer health care system of Canada were developed. These focus on accurate diagnosis, appropriate and timely management, disease monitoring, and prevention or treatment of complications of IBD or its therapy. CONCLUSIONS: These quality indicators are measurable, reflective of the evidence base and expert opinion, and define a standard of care that is at least a minimum that should be expected for IBD management in Canada. The next steps for the EPIC group involve conducting research to assess current practice across Canada as it pertains to these quality indicators and to measure the impact of each of these indicators on patient outcomes.
BACKGROUND: There is a paucity of published data regarding the quality of care of inflammatory bowel disease (IBD) in Canada. Clinical quality indicators are quantitative end points used to guide, monitor and improve the quality of patient care. In Canada, where universal health care can vary significantly among provinces, quality indicators can be used to identify potential gaps in the delivery of IBD care and standardize the approach to interprovincial management. METHODS: The Emerging Practice in IBD Collaborative (EPIC) group generated a shortlist of IBD quality indicators based on a comprehensive literature review. An iterative voting process was used to select quality indicators to take forward. In a face-to-face meeting with the EPIC group, available evidence to support each quality indicator was presented by the EPIC member aligned to it, followed by group discussion to agree on the wording of the statements. The selected quality indicators were then ratified in a final vote by all EPIC members. RESULTS: Eleven quality indicators for the management of IBD within the single-payer health care system of Canada were developed. These focus on accurate diagnosis, appropriate and timely management, disease monitoring, and prevention or treatment of complications of IBD or its therapy. CONCLUSIONS: These quality indicators are measurable, reflective of the evidence base and expert opinion, and define a standard of care that is at least a minimum that should be expected for IBD management in Canada. The next steps for the EPIC group involve conducting research to assess current practice across Canada as it pertains to these quality indicators and to measure the impact of each of these indicators on patient outcomes.
Authors: Jonathan A Leighton; Bo Shen; Todd H Baron; Douglas G Adler; Raquel Davila; James V Egan; Douglas O Faigel; Seng-Ian Gan; William K Hirota; David Lichtenstein; Waqar A Qureshi; Elizabeth Rajan; Marc J Zuckerman; Trina VanGuilder; Robert D Fanelli Journal: Gastrointest Endosc Date: 2006-04 Impact factor: 9.427
Authors: Roshan Razik; Charles N Bernstein; Justina Sam; Reka Thanabalan; Geoffrey C Nguyen Journal: Can J Gastroenterol Date: 2012-11 Impact factor: 3.522
Authors: Shanika de Silva; Christopher Ma; Marie-Claude Proulx; Marcelo Crespin; Belle S Kaplan; James Hubbard; Martin Prusinkiewicz; Andrew Fong; Remo Panaccione; Subrata Ghosh; Paul L Beck; Anthony Maclean; Donald Buie; Gilaad G Kaplan Journal: Clin Gastroenterol Hepatol Date: 2011-07-30 Impact factor: 11.382
Authors: Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: Evelyn M Clayton; Mary C Rea; Fergus Shanahan; Eamonn M M Quigley; Barry Kiely; Colin Hill; R Paul Ross Journal: Am J Gastroenterol Date: 2009-03-24 Impact factor: 10.864
Authors: Stephanie Coward; Steven J Heitman; Fiona Clement; Maria Negron; Remo Panaccione; Subrata Ghosh; Herman W Barkema; Cynthia Seow; Yvette P Y Leung; Gilaad G Kaplan Journal: Am J Gastroenterol Date: 2014-10-28 Impact factor: 10.864
Authors: Pritesh S Morar; James Hollingshead; Willem Bemelman; Nick Sevdalis; Thomas Pinkney; Graeme Wilson; Malcolm Dunlop; R Justin Davies; Richard Guy; Nicola Fearnhead; Steven Brown; Janindra Warusavitarne; Cathryn Edwards; Omar Faiz Journal: J Crohns Colitis Date: 2017-10-27 Impact factor: 9.071